Research Article
The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising Therapy
Table 1
The clinical characteristics of the mesenchymal stem cell (MSC) transplantation and comparison groups.
| | | MSC transplantation group (n = 10) n (%) | Control group (n = 20) n (%) | |
| | Baseline characteristics | | Age, median (min–max) | 51 (22–68) | 69 (22–80) | 0.015 | | Male gender | 6 (60.0) | 15 (75.0) | 0.675 | | Comorbid disease | 7/10 (70%) | 17/20 (85%) | 0.633 | | APACHE II score, median (min–max) | 27 (14–42) | 28 (14–35) | 0.779 | | SOFA score, median (min–max) | 9 (2–18) | 11 (4–18) | 0.307 |
| | Qualifying organ failure, n (%) | | Respiratory failure | 4 (40.0) | 1 (5.0) | 0.031 | | Renal failure | 3 (30.0) | 4 (20.0) | 0.657 | | Coagulation failure | 1 (10.0) | 2 (10.0) | 0.999 | | Organ hypoperfusion | 9 (90.0) | 11 (55.0) | 0.101 |
| | Baseline organ failure (hypoperfusion) | | Renal, creatinine (mg/dL) median (min–max) | 4.40 (0.21–7.80) | 1.16 (0.26–8.07) | 0.024 | | Hematologic, platelets (103/µL) median (min–max) | 156000 (26000–479000) | 200500 (18000–575000) | 0.373 | | Liver enzyme (μ/L) median (min–max) | | | | | Alanine aminotransferase (ALT) median | 34 (3–861) | 19 (5–1437) | 0.713 | | Aspartate aminotransferase (AST) median | 49 (19–158) | 26 (10–2205) | 0.231 | | Lactate (mmol/L) median (min–max) | 1.42 (0.82–3.17) | 1.69 (0.80–9.96) | 0.350 |
| | Infectious source n (%) | | Lung | 2 (20.0) | 12 (60.0) | | | Urinary | 3 (30.0) | 3 (15.0) | | | Intraabdominal | 3 (30.0) | 5 (25.0) | 0.063 | | Meningoencephalitis | 1 (10.0) | 0 (0.0) | | | Bacteraemia | 1 (10.0) | 0 (0.0) | | | ICU length of stay (survivors) | | | | | Median (min–max) | 26 (10–91) | 10 (3–32) | 0.001 | | Hospital length of stay (survivors) | | | | | Median (min–max) | 28 (16–91) | 16 (5–40) | 0.091 |
| | Clinical outcomes | | Mortality, n (%; 95% CI) | | | | | 14 day | 0 (0.0) | 6 (30.0) | 0.141 | | 28 day | 3 (30.0) | 8 (40.0) | 0.702 |
|
|
